IS7481A - Epóthílon til gjafar um munn - Google Patents

Epóthílon til gjafar um munn

Info

Publication number
IS7481A
IS7481A IS7481A IS7481A IS7481A IS 7481 A IS7481 A IS 7481A IS 7481 A IS7481 A IS 7481A IS 7481 A IS7481 A IS 7481A IS 7481 A IS7481 A IS 7481A
Authority
IS
Iceland
Prior art keywords
epothilone
oral administration
oral
administration
Prior art date
Application number
IS7481A
Other languages
English (en)
Inventor
Y. L. Lee Francis
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of IS7481A publication Critical patent/IS7481A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IS7481A 2002-04-04 2004-09-30 Epóthílon til gjafar um munn IS7481A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37010402P 2002-04-04 2002-04-04
PCT/US2003/009984 WO2003084536A1 (en) 2002-04-04 2003-04-01 Oral administration of epothilones

Publications (1)

Publication Number Publication Date
IS7481A true IS7481A (is) 2004-09-30

Family

ID=28792029

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7481A IS7481A (is) 2002-04-04 2004-09-30 Epóthílon til gjafar um munn

Country Status (9)

Country Link
US (1) US6936628B2 (is)
EP (1) EP1492529A1 (is)
JP (1) JP2005527576A (is)
AU (1) AU2003226189A1 (is)
IS (1) IS7481A (is)
NO (1) NO20044452L (is)
PL (1) PL372773A1 (is)
TW (1) TW200403994A (is)
WO (1) WO2003084536A1 (is)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
ES2752452T3 (es) 2002-05-14 2020-04-06 Dupont Nutrition Usa Inc Composiciones de hidrocoloides de celulosa microcristalinas codesgastadas por atrición y método para su fabricación
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
FR2878443B1 (fr) * 2004-08-03 2009-01-16 Promindus Actions Promotionnel Composition pharmaceutique, destinee a l'administration par voie orale de principe(s) actif(s) fortement gastro-labile(s et sa preparation
HRP20080349T3 (hr) * 2004-11-18 2009-01-31 Bristol-Myers Squibb Company Zrna premazana enteričkom smjesom koja sadrže iksabepilon
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
US20060255258A1 (en) * 2005-04-11 2006-11-16 Yongdong Wang Chromatographic and mass spectral date analysis
US7879382B2 (en) * 2005-09-30 2011-02-01 Fmc Corporation Stabilizers and compositions and products comprising same
JP2010507676A (ja) * 2006-10-27 2010-03-11 エフ エム シー コーポレーション 乾式顆粒化結合剤、生成物およびその使用
EP2009114A1 (en) * 2007-06-29 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
TW201129386A (en) * 2009-11-05 2011-09-01 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
TWI461213B (zh) * 2009-11-05 2014-11-21 Fmc Corp 作為藥物賦形劑之微晶纖維素及磷酸鈣之組合物
EP2515943A4 (en) * 2009-12-22 2014-04-30 Fmc Corp MICROCRYSTALLINE CELLULOSE AND CALCIUM CARBONATE COMPOSITIONS USEFUL AS RECOMPACTABLE PHARMACEUTICAL EXCIPIENTS
CN103037903A (zh) 2010-05-18 2013-04-10 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法
US9826763B2 (en) 2011-10-05 2017-11-28 Fmc Corporation Stabilizer composition of microcrystalline cellulose and carboxymethylcellulose, method for making, and uses
BR112014007880B1 (pt) 2011-10-05 2020-07-14 Dupont Nutrition Usa, Inc Composição estab ilizante de celulose microcristalina co-atritada e carboximetilcelulose, método de preparação, e usos
EP2787837B1 (en) 2011-12-09 2017-03-15 FMC Corporation Co-attrited stabilizer composition
GB2595203A (en) 2020-03-03 2021-11-24 Alkaloid Ad Skopje Formulation
CZ2020287A3 (cs) 2020-05-20 2021-12-01 Mendelova Univerzita V Brně Způsob přípravy nanokompozitního materiálu na bázi redukovaného grafen oxidu, dusičnanu stříbrného a octanu měďnatého, nanokompozitní materiál, přípravek jej obsahující a jeho použití
PL4062913T3 (pl) * 2020-09-02 2024-07-22 Beijing Biostar Pharmaceuticals Co., Ltd. Stały preparat doustny utidelonu

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
US5671397A (en) * 1993-12-27 1997-09-23 At&T Global Information Solutions Company Sea-of-cells array of transistors
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
ES2178093T5 (es) 1995-11-17 2009-02-16 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Derivados de epotilon y su preparacion.
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
AU753546B2 (en) 1996-11-18 2002-10-24 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
CA2273083C (en) * 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
CA2281105A1 (en) 1997-02-25 1998-09-03 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilones with a modified side chain
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
WO1998047891A1 (de) 1997-04-18 1998-10-29 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
PT1001951E (pt) 1997-07-16 2003-02-28 Schering Ag Derivados de tiazolo, processo para a sua preparacao e utilizacao
IL134419A0 (en) 1997-08-09 2001-04-30 Schering Ag Epothilone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
US6365749B1 (en) * 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
WO1999039694A2 (en) 1998-02-05 1999-08-12 Novartis Ag Compositions containing organic compounds
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
NZ506742A (en) 1998-02-25 2003-09-26 Sloan Kettering Inst Cancer Synthesis of desoxyepothilones and hydroxy acid derivative intermediates
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
IL143069A0 (en) 1998-11-20 2002-04-21 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
EP1140944B1 (en) 1998-12-22 2003-08-27 Novartis AG Epothilone derivatives and their use as antitumor agents
HUP0200296A2 (en) 1998-12-23 2002-05-29 Bristol Myers Squibb Co Microbial transformation method for the preparation of an epothilone
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
SK11852001A3 (sk) 1999-02-18 2002-04-04 Schering Aktiengesellschaft Deriváty epotiólonu, spôsoby ich výroby a ich farmaceutické použitie
US6262094B1 (en) * 1999-02-22 2001-07-17 Bristol-Myers Squibb Company C-21 modified epothilones
US6211412B1 (en) * 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
HUP0303175A2 (hu) * 2001-02-20 2003-12-29 Bristol-Myers Squibb Co. Epotilonszármazékok alkalmazása makacs tumorok kezelésére alkalmas gyógyszerkészítmény előállítására
KR20040028720A (ko) * 2001-02-20 2004-04-03 브리스톨-마이어스스퀴브컴파니 치료불응성 종양 치료용 에포틸론 유도체
CA2440555A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives

Also Published As

Publication number Publication date
PL372773A1 (en) 2005-08-08
WO2003084536A1 (en) 2003-10-16
NO20044452L (no) 2004-12-07
JP2005527576A (ja) 2005-09-15
US6936628B2 (en) 2005-08-30
AU2003226189A1 (en) 2003-10-20
EP1492529A1 (en) 2005-01-05
TW200403994A (en) 2004-03-16
US20030220378A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
IS7481A (is) Epóthílon til gjafar um munn
PT1501534E (pt) Formulacoes farmaceuticas
ATE549329T1 (de) Chinazoline verbindungen
IS6994A (is) Arípíprazóllausn til gjafar um munn
NO20052914D0 (no) Terapeutiske forbindelser
ATE460418T1 (de) Heterocyclocarboxamidderivate
ATE450506T1 (de) Indol-3-schwefelderivate
ATE467631T1 (de) Chinuclidinamidderivate
ATE438644T1 (de) Chinazolinderivate
CY2018005I2 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
PL377495A1 (pl) Stały lek do stosowania doustnego
DE60307512D1 (de) 3h-chinazoline -4-on derivaten
PT1558263E (pt) Composicao farmaceutica de libertacao prolongada
DE60326998D1 (de) Orale zubereitung
NO20044188L (no) Kontrollerte frigjoringsdoseformer
ATE423771T1 (de) Tetrahydrochinolinderivate
EP1478356A4 (en) THERAPEUTIC COMPOUNDS
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
NO20043633L (no) Oral doseringsform for kontrollert medikamentfrigivning
NO20034952D0 (no) Farmasöytiske forbindelser
IL174009A0 (en) Melt-formulated, multi-particulate oral dosage form
IS7581A (is) Lyfjasamsetning
NO20044164L (no) Farmasoytiske sammensetninger
ITBO20020101A0 (it) Riunito dentale